[Irvine-Gass syndrome. IV. Etiology. V. Pathogenesis. VI. Treatment].
D000328:Adult; D000367:Age Factors; D000368:Aged; D002387:Cataract Extraction / Q000009:adverse effects*; D002918:Chymotrypsin / Q000009:adverse effects; D003315:Cornea / Q000601:surgery; D004487:Edema / Q000209:etiology* / Q000517:prevention & control / Q000601:surgery / Q000628:therapy; D005128:Eye Diseases / Q000150:complications; D005260:Female; D006801:Humans; D007498:Iris / Q000601:surgery; D008266:Macula Lutea; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011241:Prednisone / Q000627:therapeutic use; D012164:Retinal Diseases / Q000209:etiology* / Q000517:prevention & control / Q000601:surgery / Q000628:therapy; D013577:Syndrome; D014822:Vitreous Body
D002918:Chymotrypsin; D011241:Prednisone
Le syndrome d'Irvine-Gass. IV. Etiologie. V. Pathogénie. VI. Traitement.